Condition: High Risk Smoldering Multiple Myeloma · Sponsor: Institute of Hematology & Blood Diseases Hospital, China
The purpose of this study is to evaluate the safety and efficacy of CM-336, which is a BCMA/CD3 BiTE, in the treatment of high risk smoldering multiple myeloma.
This description comes directly from the study's public registry record.
Gang An, MD, PhD · +86 022-23909171 · angang@ihcams.ac.cn
jieqiong zhou, MBBS · 008617827063445 · zhoujieqiong@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06745687